DK1526172T3 - Fremgangsmåde til replikation af influenzavira i cellekultur og ved fremgangsmåden opnåelige influenzavira - Google Patents

Fremgangsmåde til replikation af influenzavira i cellekultur og ved fremgangsmåden opnåelige influenzavira

Info

Publication number
DK1526172T3
DK1526172T3 DK05075182.5T DK05075182T DK1526172T3 DK 1526172 T3 DK1526172 T3 DK 1526172T3 DK 05075182 T DK05075182 T DK 05075182T DK 1526172 T3 DK1526172 T3 DK 1526172T3
Authority
DK
Denmark
Prior art keywords
influenza viruses
cell culture
obtainable
replicating
viruses
Prior art date
Application number
DK05075182.5T
Other languages
English (en)
Inventor
Albrecht Groner
Juergen Vorlop
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7790127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1526172(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK1526172T3 publication Critical patent/DK1526172T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
DK05075182.5T 1996-04-01 1997-04-01 Fremgangsmåde til replikation af influenzavira i cellekultur og ved fremgangsmåden opnåelige influenzavira DK1526172T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19612967A DE19612967A1 (de) 1996-04-01 1996-04-01 Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
EP97915628.8A EP0891420B2 (en) 1996-04-01 1997-04-01 Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process

Publications (1)

Publication Number Publication Date
DK1526172T3 true DK1526172T3 (da) 2011-10-03

Family

ID=7790127

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05075182.5T DK1526172T3 (da) 1996-04-01 1997-04-01 Fremgangsmåde til replikation af influenzavira i cellekultur og ved fremgangsmåden opnåelige influenzavira
DK97915628.8T DK0891420T4 (da) 1996-04-01 1997-04-01 Fremgangsmåde til replikation af influenzavirus i cellekultur samt de ved fremgangsmåden opnåelige influenzavirus

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97915628.8T DK0891420T4 (da) 1996-04-01 1997-04-01 Fremgangsmåde til replikation af influenzavirus i cellekultur samt de ved fremgangsmåden opnåelige influenzavirus

Country Status (13)

Country Link
US (2) US20030119183A1 (da)
EP (3) EP0891420B2 (da)
JP (6) JP4447054B2 (da)
AT (2) ATE513905T1 (da)
CA (1) CA2250078C (da)
DE (3) DE19612967A1 (da)
DK (2) DK1526172T3 (da)
ES (3) ES2367081T3 (da)
HK (2) HK1075467A1 (da)
LU (1) LU91381I2 (da)
NL (1) NL300307I1 (da)
PT (2) PT891420E (da)
WO (1) WO1997037001A1 (da)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
WO1999023206A1 (en) * 1997-10-31 1999-05-14 Merck & Co., Inc. A method of improved mixing of a varicella-infected cell culture in roller bottles
CA2308111C (en) * 1997-10-31 2010-12-21 Merck & Co., Inc. A method of improved mixing in roller bottles
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
ATE473272T1 (de) 2000-03-03 2010-07-15 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
AU2002366267B2 (en) * 2001-11-19 2007-05-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
ES2295465T3 (es) 2002-09-16 2008-04-16 Pan-Biotech Gmbh Procedimiento para el cultivo de celulas, en especial de celulas humanas o de animales.
WO2004033616A1 (de) * 2002-09-16 2004-04-22 Pan-Biotech Gmbh Einrichtung zur kultivierung von zellen, insbesondere menschlicher oder tierischer zellen
US7270990B2 (en) 2003-06-20 2007-09-18 Microbix Biosystems, Inc. Virus production
EP1722815A1 (en) 2004-03-09 2006-11-22 Chiron Corporation Influenza virus vaccines
CN101094915A (zh) * 2004-05-20 2007-12-26 益得生物医学公司 生产流感疫苗的方法
WO2006078294A2 (en) 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
CA2890962A1 (en) * 2004-09-09 2006-03-16 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Decreasing potential iatrogenic risks associated with influenza vaccines
KR20120128162A (ko) 2004-12-08 2012-11-26 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
WO2006071563A2 (en) 2004-12-23 2006-07-06 Medimmune Vaccines, Inc. Non-tumorigenic mdck cell line for propagating viruses
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
ES2359214T5 (es) 2005-11-01 2014-10-08 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual por tratamiento con beta-propiolactona
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PT1951299E (pt) 2005-11-04 2012-02-28 Novartis Vaccines & Diagnostic Vacinas contra a gripe que incluem combinações de adjuvantes particulados e imuno-potenciadores
CA2628206A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
BRPI0618254A2 (pt) 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido
EP1945252B1 (en) 2005-11-04 2013-05-29 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
JP6087041B2 (ja) 2006-01-27 2017-03-08 ノバルティス アーゲー 血球凝集素およびマトリックスタンパク質を含むインフルエンザウイルスワクチン
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
CA2647985C (en) 2006-03-31 2014-12-30 Warf-Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
US7883844B2 (en) 2006-05-11 2011-02-08 Juridical Foundation The Chemosero-Therapeutic Research Institute Method for propagating influenza virus
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
ES2536401T3 (es) 2006-09-11 2015-05-25 Novartis Ag Fabricación de vacunas contra virus de la gripe sin usar huevos
KR20140075022A (ko) 2006-09-15 2014-06-18 메디뮨 엘엘씨 높은 역가로 바이러스 증식을 지원하는 ｍｄｃｋ 세포주 및 이를 이용한 생물반응기 공정
ES2480491T3 (es) 2006-12-06 2014-07-28 Novartis Ag Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe
US20100239606A1 (en) 2007-05-04 2010-09-23 Baxter International Inc. Two-Step Temperature Profile for the Propagation of Viruses
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
BRPI0813866A2 (pt) 2007-06-27 2015-01-06 Novartis Ag Vacinas contra influenza com baixo teor de aditivos
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
CN102216450B (zh) 2008-09-24 2014-05-14 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
EP2396031A1 (en) 2009-02-10 2011-12-21 Novartis AG Influenza vaccines with increased amounts of h3 antigen
CA2752039A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
DK2396032T3 (da) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenzavacciner med reducerede mængder squalen
KR20120027276A (ko) 2009-04-27 2012-03-21 노파르티스 아게 인플루엔자를 예방하기 위한 면역증강된 백신
CN102597246B (zh) 2009-05-21 2014-02-26 诺华股份有限公司 使用非内源pol I启动子的反向遗传
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CN102666860B (zh) 2009-07-31 2015-06-17 诺华股份有限公司 反向遗传系统
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
ES2454815T3 (es) 2009-10-20 2014-04-11 Novartis Ag Métodos mejorados de genética inversa para la recuperación de virus
EP2493912B1 (en) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US20130203151A1 (en) 2010-04-26 2013-08-08 Scott Balsitis Production of alphavirus replicon particles in packaging cells
CN103025350A (zh) 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法
PT2575873E (pt) 2010-06-01 2016-03-04 Novartis Ag Concentração de antigénios de vacinas com liofilização
ES2825712T3 (es) 2010-06-01 2021-05-17 Seqirus Uk Ltd Concentración de antígenos de vacuna contra la influenza sin liofilización
ES2531577T3 (es) 2010-08-20 2015-03-17 Novartis Ag Conjuntos de agujas para la administración de vacuna soluble contra la gripe
BR112013008700B8 (pt) 2010-10-11 2022-10-04 Novartis Ag Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante
SI2667892T1 (sl) 2011-01-26 2019-05-31 Glaxosmithkline Biologicals Sa Imunizacijski režim proti RSV
EP2686423A4 (en) 2011-03-14 2015-01-28 Nat Res Council Canada METHOD FOR PRODUCING VIRUSES IN CELLS
CA2872033A1 (en) 2011-10-11 2013-04-18 Novartis Ag Recombinant self-replicating polycistronic rna molecules
US20140348863A1 (en) 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
WO2013057715A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
CA2813723A1 (en) 2012-03-02 2013-09-02 Novartis Ag Influenza virus reassortment
JP5918870B2 (ja) 2012-03-06 2016-05-18 クルセル ホランド ベー ヴェー インフルエンザに対する改善されたワクチン接種
CA2875752A1 (en) 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
WO2014086732A2 (en) 2012-12-03 2014-06-12 Novartis Ag Influenza virus reassortment
JP6525469B2 (ja) 2013-03-13 2019-06-05 ノバルティス アーゲー インフルエンザｂ型ウイルス再集合
JP2016521282A (ja) 2013-05-10 2016-07-21 ノバルティス アーゲー インフルエンザワクチンにおけるナルコレプシーのリスクの回避
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
CA2914604A1 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
US10416171B2 (en) 2015-07-07 2019-09-17 Seqirus UK Limited Influenza potency assays
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
US11730802B2 (en) 2017-11-03 2023-08-22 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
CA3137652A1 (en) 2019-05-08 2020-11-12 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
WO2021099419A1 (en) 2019-11-18 2021-05-27 Seqirus UK Limited Method for producing reassortant influenza viruses
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1278075B (de) * 1964-06-22 1968-09-19 Norden Lab Inc Verwendung von Gewebekulturen zur Zuechtung von Viren fuer die Gewinnung von Impfstoffen
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
USRE33164E (en) * 1979-05-15 1990-02-13 Mobay Corporation Influenza vaccine production in liquid cell culture
CA1122527A (en) * 1979-05-15 1982-04-27 Karen K. Brown Influenza vaccine production in liquid cell culture
US5013663A (en) * 1983-06-15 1991-05-07 American Home Products Corporation Canine corona virus vaccine
US4783411A (en) * 1984-10-22 1988-11-08 Janis Gabliks Influenza-A virus vaccine from fish cell cultures
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5646033A (en) * 1994-11-30 1997-07-08 Dyncorp African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US6514502B1 (en) * 1999-01-26 2003-02-04 Schering-Plough Veterinary Corporation Propagation of bovine cononavirus in chinese hamster ovary cells

Also Published As

Publication number Publication date
DE69732407T2 (de) 2006-01-19
ES2435726T3 (es) 2013-12-23
ATE288479T1 (de) 2005-02-15
DE69732407D1 (de) 2005-03-10
JP2011212020A (ja) 2011-10-27
PT1526172E (pt) 2011-09-01
EP0891420A1 (en) 1999-01-20
ATE513905T1 (de) 2011-07-15
ES2236799T5 (es) 2014-01-23
ES2367081T3 (es) 2011-10-28
US20070117131A1 (en) 2007-05-24
US20030119183A1 (en) 2003-06-26
EP0891420B1 (en) 2005-02-02
CA2250078C (en) 2009-06-23
DE69732407T3 (de) 2014-07-10
DK0891420T3 (da) 2005-04-25
EP1526172A1 (en) 2005-04-27
CA2250078A1 (en) 1997-10-09
JP2013116124A (ja) 2013-06-13
EP2172543B1 (en) 2013-08-21
PT891420E (pt) 2005-06-30
DK0891420T4 (da) 2014-01-20
EP2172543A1 (en) 2010-04-07
JP5264843B2 (ja) 2013-08-14
EP0891420B2 (en) 2013-11-20
JP2000507825A (ja) 2000-06-27
DE122007000082I1 (de) 2009-01-02
NL300307I1 (nl) 2008-02-01
EP1526172B1 (en) 2011-06-22
JP2008245659A (ja) 2008-10-16
WO1997037001A1 (en) 1997-10-09
HK1142093A1 (en) 2010-11-26
DE19612967A1 (de) 1997-10-02
LU91381I2 (fr) 2008-01-30
ES2236799T3 (es) 2005-07-16
JP4447054B2 (ja) 2010-04-07
JP2010275321A (ja) 2010-12-09
HK1075467A1 (en) 2005-12-16
JP2006296437A (ja) 2006-11-02

Similar Documents

Publication Publication Date Title
DK1526172T3 (da) Fremgangsmåde til replikation af influenzavira i cellekultur og ved fremgangsmåden opnåelige influenzavira
DK0904351T3 (da) Dyreceller og fremgangsmåder til replikationen af influenzavirus
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
DK0918848T3 (da) Fremgangsmåder til at behandle kræftsygdomme og patogene infektioner ved anvendelse af antigenpræsenterende celler påfyldt med RNA
DE69434931D1 (de) Methode zur selektiven inaktivierung der viralen replication
DK0755258T3 (da) Fremgangsmåde til behandling af sygdom ved at anvende Sertoli-celler og allo-transplantater eller xeno-transplantater
ATE466932T1 (de) Vermehrung von viren in zellkultur
DK1650307T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner ved anvendelse af apoptoseinhibitorer
BRPI0407636A (pt) meio de cultura de células, linhagem de células animais, métodos para produzir um meio de cultura condicionado, células animais, uma cultura de células animais, vìrus em uma cultura de células animais, ou, de preferência, humanas diplóides dependentes de ancoragem, método para produzir uma vacina, e, população de vìrus
CY1110695T1 (el) Μεθοδοι για την δημιουργια υψηλου τιτλου ανευ-βοηθου παρασκευασματων απελευθερωμενων ανασυνδυασμενων aav φορεων
DK0493115T3 (da) Fremgangsmåde til isolering af DNA
DE60136558D1 (de) Verfahren zur kultivierung humaner chondrozyten
DK0506714T3 (da) Matrix med adhærent bundne celler og fremgangsmåde til frembringelse af virus/virusantigener
DK1517987T3 (da) Bomuldsrottelungeceller til virusdyrkning
WO2003063783A3 (en) Multiple virus replicon culture systems
FR2855183B1 (fr) Procede de clonage du rat par transfert nucleaire
DK1064294T3 (da) 5-imino-13-deoxyanthracyclin-derivater, deres vendelse og fremgangsmåde til fremstilling af disse
DK0674007T3 (da) Fremgangsmåde til fremstilling af pilocarpin
DK0399545T3 (da) Fremgangsmåde til dekontaminering af mycoplasmaholdige cellekulturer
CA2250714A1 (en) Animal cells and processes for the replication of influenza viruses
ES1033972U (es) Marco perfeccionado.
DK1303635T3 (da) Fremgangsmåde til selektiv overlevelse eller selektiv vækst af en målcelle ved anvendelse af et konjugat til terapi og/eller diagnostik
DK306479A (da) N-cyclohexyl-n-methoxyacetoacetamid, fremgangsmaade til fremstilling deraf og anvendelse deraf til fremstilling af o-methyl-n-cyclohexyl-2,5-dimethylfuran-3-hydroxamsyre
ITRM940091A0 (it) Procedimento per la preparazione di colture cellulari di eisenia foetida (anellidi, oligocheti).